About US
Contact us
-
Samsung Biologics sidesteps CDMO industry trend with 23% growth in 2024After revenue boomed for biopharma manufacturers during the COVID pandemic, sales have stagnated for several CDMO giants, including Lonza,Thermo FisherandCatalent. But Korean powerhouse Samsung Biolo2025/1/16
-
J&J stands by sales growth ambitions—and points to potential Tremfya boon—as Stelara biosimilars take holdAs Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & Johnson is confident it can eke out revenue growth this year despite the s2025/1/16
-
Johnson & Johnson's Spravato gains FDA nod to be used as a monotherapyAlready on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the FDA hasblessedthe nasal spray to be used as a monotherapy for major dep2025/1/14
-
Sanofi API plant hit with FDA warning letter detailing quality, consistency flubsDespite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a U.S. drug ingredients plant tied to its longstanding subsidiary Genzyme. T2025/1/14
-
Large study of Novo, Lilly weight loss drugs shows decrease in risk of Alzheimer'sAs evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s tirzepatide2025/1/9
-
Sage sues Biogen as analyst detects little interest in buyout at original offer priceSage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience partner. The lawsuit is sealed in Delaware’s Court of Chancery, but in a se2025/1/9
-
Citius Oncology weighs strategic options on road to launching newly-approved lymphoma medAfter nabbing an FDA approval last summer for its T-cell lymphoma treatment Lymphir, Citius Oncology is eyeing strategic alternatives. The company, a subsidiary of Citius Pharmaceuticals, is explorin2025/1/7
-
Novo asks FDA to restrict Victoza compounding amid GLP-1 outsourcing rowAs concerns around knockoffs of newer GLP-1 drugs like Ozempic and Wegovy take center stage, Novo Nordisk’s efforts to ward off competition against its aging diabetes blockbuster Victoza have been qu2025/1/7
-
2025 forecast: After Novo, Lilly expansion sprees, 'positive signals' emerge around future supply of GLP-1 drugsWhile the recent launches of GLP-1 drugs from Novo Nordisk and Eli Lilly have been nothing short of a staggering financial success, the rollouts have consistently been hamstrung by manufacturing and2025/1/2
-
Roche projected to claim pharma's 2025 sales crown as Novo, Lilly climb rankings: EvaluateThe story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine rivals continue to smooth over supply issues and rake in dividends from their r2025/1/2